TRPHARM
9
0
0
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 85/100
22.2%
2 terminated/withdrawn out of 9 trials
0.0%
-86.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (9)
An Observational Study for Evaluation of for the Prevalence of Cerebrotendinous Xanthomatosis (CTX) Disease
Role: lead
Investigation of ADA Enzyme Deficiency
Role: lead
Observational Study Evaluating the Prevalence of Enzyme Deficiency in Pulmonology Clinics (ADA)
Role: lead
Prevalence of Adenosine Deaminase (ADA) Enzyme Deficiency Disease in Adult Patients With Pulmonary Alveolar Proteinosis
Role: lead
Evaluation of Adenosine Deaminase (ADA) Enzyme Deficiency in Patients With Lymphopenia and/or Elevated Immunoglobulin E
Role: lead
A Compassionate Use Program to Provide Access to Sodium Thiosulfate
Role: lead
A Study on the Prevalence of Mutation of Cerebrotendinous Xanthomatosis (CTX)
Role: lead
The Prevalence of CTX Disorder in Juvenile Cataract Cases in Turkey
Role: lead
Bioequivalence and Safety Study of Bevacizumab-biosimilar (RPH-001) Compared to Bevacizumab-innovator
Role: lead
All 9 trials loaded